Loading filters...
Publications per Year (224 total)
1
·
2
1995
2
·
2
·
3
·
9
·
6
2000
5
·
4
·
1
·
1
·
1
2005
1
·
13
·
5
·
16
·
12
2010
14
·
8
·
1
·
5
·
1
2015
2
·
2
·
2
·
5
·
12
2020
15
·
9
·
12
·
20
·
17
2025
15
·
Loaded
Click to load
50 / 224 papers loaded(scroll for more)
202613 papers
GeneralResectable2026
Long-term Outcomes in Gallbladder Cancer Patients Treated with Curative-Intent Resection: Adjuvant Chemotherapy Versus Observation in a Multicenter Propensity Score-Matched Study.
Yu LY et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Preoperative Chemotherapy with Gemcitabine and Cisplatin for Biliary Tract Cancer Does Not Affect Liver Regeneration Induced by Portal Vein Embolization.
Hyakutake Y et al. Ann Surg Oncol. 2026
GeneralAdvanced/Metastatic2026
Outcomes After Resection for Multiple Intrahepatic Cholangiocarcinoma-A National Population-Based Study.
Jansson H et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Association Between Metabolic Syndrome and Long-Term Prognosis in Patients with Perihilar Cholangiocarcinoma Treated with Curative-Intent Resection: A Multicenter Study.
Liu ZP et al. Ann Surg Oncol. 2026
GeneralResectable2026
Retroperitoneal-First Laparoscopic Approach (Retlap) for Bile Duct Resection in Pancreaticobiliary Maljunction (PBM): A Novel and Reasonable Approach to Intrapancreatic Bile Duct.
Karasuyama T et al. Ann Surg Oncol. 2026
FGFR alteredAdvanced/Metastatic2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.
Abou-Alfa GK et al. ESMO Open. 2026
GeneralAll Stages2026
Extracellular Vesicle-Mediated O-GlcNAcase Transfer Drives Neuronal Necroptosis to Facilitate Gallbladder Cancer Perineural Invasion.
Zhao J et al. Cancer Res. 2026
GeneralResectable2026
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Shi GM et al. N Engl J Med. 2026
GeneralAdvanced/Metastatic2026
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma.
Zhixing L et al. Hepatology. 2026
IDH1/2 mutantAll Stages2026
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.
Wan J et al. Clin Cancer Res. 2026
GeneralAdvanced/Metastatic2026
Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Nasar N et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy.
Yu M et al. J Hepatol. 2026
GeneralAll Stages2026
Reappraisal of the Clinical Utility of Hi-Cut Pancreaticoduodenectomy for Widespread Distal Cholangiocarcinoma: A Less Invasive Alternative to Hepatopancreatoduodenectomy.
Umino R et al. Ann Surg Oncol. 2026
201114 papers
GeneralAll Stages2011
Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer.
Kitamura K et al. J Hepatobiliary Pancreat Sci. 2011
GeneralAdvanced/Metastatic2011
Trends in the incidence and management of biliary tract cancer: a French population-based study.
Lepage C et al. J Hepatol. 2011
GeneralAll Stages2011
New staging system and a registry for perihilar cholangiocarcinoma.
Deoliveira ML et al. Hepatology. 2011
GeneralAdvanced/Metastatic2011
Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival.
Schiffman SC et al. Ann Surg Oncol. 2011
GeneralAdvanced/Metastatic2011
Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
Kim KP et al. Br J Cancer. 2011
GeneralAll Stages2011
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.
de Jong MC et al. J Clin Oncol. 2011
GeneralAdvanced/Metastatic2011
Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization.
Fabris L et al. Hepatology. 2011
GeneralResectable2011
Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
Murakami Y et al. Ann Surg Oncol. 2011
GeneralAll Stages2011
Pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: the clinical impact of a new surgical procedure; pylorus-resecting pancreaticoduodenectomy.
Kawai M et al. J Hepatobiliary Pancreat Sci. 2011
GeneralAll Stages2011
A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score.
Jiang W et al. Ann Oncol. 2011
GeneralAll Stages2011
Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Uchiyama K et al. J Hepatobiliary Pancreat Sci. 2011
GeneralAll Stages2011
Angiogenesis: a prognostic determinant in pancreatic cancer?
van der Zee JA et al. Eur J Cancer. 2011
GeneralAll Stages2011
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J et al. J Hepatobiliary Pancreat Sci. 2011
GeneralResectable2011
Preoperative serum CA 19-9 level as a predictive factor for recurrence after curative resection in biliary tract cancer.
Chung MJ et al. Ann Surg Oncol. 2011
20125 papers
GeneralAll Stages2012
Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma.
Neuhaus P et al. Ann Surg Oncol. 2012
GeneralResectable2012
Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.
Ariizumi S et al. Ann Surg Oncol. 2012
GeneralAll Stages2012
Right trisectionectomy with principle en bloc portal vein resection for right-sided hilar cholangiocarcinoma: no-touch technique.
Machado MA et al. Ann Surg Oncol. 2012
GeneralResectable2012
Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy.
Palta M et al. Ann Surg Oncol. 2012
GeneralAll Stages2012
Is port site resection necessary in the surgical management of gallbladder cancer?
Maker AV et al. Ann Surg Oncol. 2012
200912 papers
GeneralAdvanced/Metastatic2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
Overman MJ et al. J Clin Oncol. 2009
GeneralAdvanced/Metastatic2009
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.
Valle JW et al. Br J Cancer. 2009
GeneralAll Stages2009
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia.
Kanai M et al. Ann Oncol. 2009
GeneralAdvanced/Metastatic2009
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Wagner AD et al. Br J Cancer. 2009
GeneralAll Stages2009
Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Kim KH et al. Ann Surg Oncol. 2009
GeneralAll Stages2009
Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients.
Yedibela S et al. Ann Surg Oncol. 2009
GeneralAll Stages2009
Expression and clinical significance of cell cycle regulatory proteins in gallbladder and extrahepatic bile duct cancer.
Kim WB et al. Ann Surg Oncol. 2009
GeneralAll Stages2009
Initial presentation and management of hilar and peripheral cholangiocarcinoma: is a node-positive status or potential margin-positive result a contraindication to resection?
Nguyen KT et al. Ann Surg Oncol. 2009
GeneralAll Stages2009
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3.
Selaru FM et al. Hepatology. 2009
GeneralAdvanced/Metastatic2009
Relationship between microvessel count and postoperative survival in patients with intrahepatic cholangiocarcinoma.
Nanashima A et al. Ann Surg Oncol. 2009
GeneralAll Stages2009
Prognostic molecular markers in cholangiocarcinoma: a systematic review.
Briggs CD et al. Eur J Cancer. 2009
GeneralAdvanced/Metastatic2009
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.
Laurent S et al. Ann Oncol. 2009
20106 papers
GeneralResectable2010
Major hepatectomy for perihilar cholangiocarcinoma.
Unno M et al. J Hepatobiliary Pancreat Sci. 2010
GeneralAll Stages2010
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma.
Nakanishi Y et al. J Hepatobiliary Pancreat Sci. 2010
GeneralAll Stages2010
Surgical strategy for mucin-producing bile duct tumor.
Ohtsuka M et al. J Hepatobiliary Pancreat Sci. 2010
GeneralAdvanced/Metastatic2010
Surgical treatment of hilar cholangiocarcinoma in the "new era": the Nagoya University experience.
Igami T et al. J Hepatobiliary Pancreat Sci. 2010
GeneralResectable2010
Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience.
Rocha FG et al. J Hepatobiliary Pancreat Sci. 2010
GeneralAll Stages2010
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types.
Hummel R et al. Eur J Cancer. 2010